Literature DB >> 30387454

Oral cancer and tobacco: developments in harm reduction.

M N Pemberton1.   

Abstract

Oral squamous cell carcinoma is associated with the use of tobacco products. The predominant addictive substance in tobacco is nicotine, however, the major carcinogenic substances are in the other components of the tobacco leaf. The highest risk from tobacco use arises from combustion in the form of cigarettes. While cigarette consumption remains prevalent in the developing world, in the UK the rates of smoking are falling. In Sweden, modified smokeless tobacco in the form of snus has been available for many years and has contributed to reduced levels of smoking. In high income countries, new forms of tobacco consumption and nicotine delivery products have been developed over the last few years. These include heat-not-burn cigarettes and electronic cigarettes, and these products are now being actively marketed by many companies, including the tobacco industry. This paper reviews this changing pattern of tobacco and nicotine consumption and the current evidence regarding the risk of these products causing oral cancer.

Entities:  

Year:  2018        PMID: 30387454     DOI: 10.1038/sj.bdj.2018.928

Source DB:  PubMed          Journal:  Br Dent J        ISSN: 0007-0610            Impact factor:   1.626


  28 in total

1.  Electronic cigarettes for smoking cessation: a randomised controlled trial.

Authors:  Christopher Bullen; Colin Howe; Murray Laugesen; Hayden McRobbie; Varsha Parag; Jonathan Williman; Natalie Walker
Journal:  Lancet       Date:  2013-09-09       Impact factor: 79.321

2.  A long-term follow-up study on the natural course of snus-induced lesions among Swedish snus users.

Authors:  Ann Roosaar; Anna L V Johansson; Gonilla Sandborgh-Englund; Olof Nyrén; Tony Axéll
Journal:  Int J Cancer       Date:  2006-07-15       Impact factor: 7.396

3.  Oral lesions associated with betel quid and tobacco chewing habits.

Authors:  R B Zain; P C Gupta; S Warnakulasuriya; P Shrestha; N Ikeda; T Axell
Journal:  Oral Dis       Date:  1997-09       Impact factor: 3.511

4.  Rise of a new superpower: health and China's global trade ambitions.

Authors:  Flynn Murphy
Journal:  BMJ       Date:  2018-02-09

Review 5.  Metabolism and disposition kinetics of nicotine.

Authors:  Janne Hukkanen; Peyton Jacob; Neal L Benowitz
Journal:  Pharmacol Rev       Date:  2005-03       Impact factor: 25.468

6.  Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy.

Authors:  S Franceschi; R Talamini; S Barra; A E Barón; E Negri; E Bidoli; D Serraino; C La Vecchia
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

7.  EffiCiency and Safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study.

Authors:  Pasquale Caponnetto; Davide Campagna; Fabio Cibella; Jaymin B Morjaria; Massimo Caruso; Cristina Russo; Riccardo Polosa
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

8.  How has the availability of snus influenced cigarette smoking in Norway?

Authors:  Ingeborg Lund; Karl Erik Lund
Journal:  Int J Environ Res Public Health       Date:  2014-11-13       Impact factor: 3.390

Review 9.  Electronic cigarettes for smoking cessation.

Authors:  Jamie Hartmann-Boyce; Hayden McRobbie; Chris Bullen; Rachna Begh; Lindsay F Stead; Peter Hajek
Journal:  Cochrane Database Syst Rev       Date:  2016-09-14

Review 10.  Nicotine: Carcinogenicity and Effects on Response to Cancer Treatment - A Review.

Authors:  Tore Sanner; Tom K Grimsrud
Journal:  Front Oncol       Date:  2015-08-31       Impact factor: 6.244

View more
  1 in total

Review 1.  The World of Oral Cancer and Its Risk Factors Viewed from the Aspect of MicroRNA Expression Patterns.

Authors:  Ovidiu Aghiorghiesei; Oana Zanoaga; Andreea Nutu; Cornelia Braicu; Radu Septimiu Campian; Ondine Lucaciu; Ioana Berindan Neagoe
Journal:  Genes (Basel)       Date:  2022-03-26       Impact factor: 4.141

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.